GEN Exclusives

More »

GEN Poll

More »
Dec 30, 2011

IPOs in 2012

After years of deep freeze, signs of life exist in the biopharma IPO market. Sure, the number of IPOs this year (13) was fewer than 2010 (16). Of the 26 launched since 2010, two-thirds now trade at a loss to investors. But some signs of hope exist judging from a smaller percentage of firms discounting on their IPOs this year compared to last year as well as their post-IPO performance. Aveo Pharmaceuticals, which went public in March 2010, has seen its share price zoom 84% since it went public. Of the two most recent biopharma companies to go public, one is trading above its IPO price, while another is unchanged. What will the IPO market look like next year?

Do you think the IPO window will swing open wider in 2012?

Yes
 
  51.1%
No
 
  46.7%
Undecided
 
  2.2%

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

Be sure to take the GEN Poll

Using CRISPRs to Tame GMOs

With more climate-induced droughts and insect infestations on the horizon do you think technologies like CRISPR will change a lot of people’s minds about GMOs, including genetically engineered foods?

More »